Esperion Therapeutics (ESPR) Return on Sales (2019 - 2026)

Esperion Therapeutics' Return on Sales history runs 8 years deep, the most recent figure standing at 0.0% for Q1 2026.

• Quarterly Return on Sales changed 0.0% year-over-year to 0.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.0% (changed 0.0% YoY) and the FY2025 annual result came in at 0.0%, changed 0.0% from the prior year.
• Return on Sales was 0.0% for Q1 2026 at Esperion Therapeutics, down from 0.0% in the prior quarter.
• Across five years, Return on Sales topped out at 0.0% in Q1 2024 and bottomed at 0.04% in Q2 2022.
• A 5-year average of 0.01% and a median of 0.01% in 2025 frame the typical range for Return on Sales.
• Peak annual rise in Return on Sales reached 8 bps in 2022, while the deepest fall reached 2 bps in 2022.
• Esperion Therapeutics' Return on Sales stood at 0.03% in 2022, then soared by 41 bps to 0.02% in 2023, then jumped by 76 bps to 0.0% in 2024, then surged by 188 bps to 0.0% in 2025, then tumbled by 189 bps to 0.0% in 2026.
• Business Quant data shows ESPR's Return on Sales at 0.0% in Q1 2026, 0.0% in Q4 2025, and 0.0% in Q3 2025.